ASSESSING THE RISK OF BIAS IN CLINICAL TRIALS FOR HEALTH TECHNOLOGY ASSESSMENTS: SHOULD EXISTING TOOLS REFLECT THE ICH E9(R1) ADDENDUM ON ESTIMANDS AND SENSITIVITY ANALYSES?

被引：0
|
作者：
Poythress, J. [1 ]
Morga, A. [2 ]
机构：
[1] Astellas Pharma Global Dev Inc, Chicago, IL USA
[2] Astellas Pharma Europe Ltd, Addlestone, England
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HTA50
引用
收藏
页码：S329 / S329
页数：1
相关论文
共 10 条
  • [1] The estimands framework: a primer on the ICH E9(R1) addendum
    Kahan, Brennan C.
    Hindley, Joanna
    Edwards, Mark
    Cro, Suzie
    Morris, Tim P.
    BMJ-BRITISH MEDICAL JOURNAL, 2024, 384
  • [2] Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) Into Practice
    Bohdana Ratitch
    James Bell
    Craig Mallinckrodt
    Jonathan W. Bartlett
    Niti Goel
    Geert Molenberghs
    Michael O’Kelly
    Pritibha Singh
    Ilya Lipkovich
    Therapeutic Innovation & Regulatory Science, 2020, 54 : 324 - 341
  • [3] Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) Into Practice
    Ratitch, Bohdana
    Bell, James
    Mallinckrodt, Craig
    Bartlett, Jonathan W.
    Goel, Niti
    Molenberghs, Geert
    O'Kelly, Michael
    Singh, Pritibha
    Lipkovich, Ilya
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2020, 54 (02) : 324 - 341
  • [4] Aligning Estimators With Estimands in Clinical Trials: Putting the ICH E9(R1) Guidelines Into Practice
    Mallinckrodt, C. H.
    Bell, J.
    Liu, G.
    Ratitch, B.
    O'Kelly, M.
    Lipkovich, I
    Singh, P.
    Xu, L.
    Molenberghs, G.
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2020, 54 (02) : 353 - 364
  • [5] Aligning Estimators With Estimands in Clinical Trials: Putting the ICH E9(R1) Guidelines Into Practice
    C. H. Mallinckrodt
    J. Bell
    G. Liu
    B. Ratitch
    M. O’Kelly
    I. Lipkovich
    P. Singh
    L. Xu
    G. Molenberghs
    Therapeutic Innovation & Regulatory Science, 2020, 54 : 353 - 364
  • [6] Defining Efficacy Estimands in Clinical Trials: Examples Illustrating ICH E9(R1) Guidelines
    Bohdana Ratitch
    Niti Goel
    Craig Mallinckrodt
    James Bell
    Jonathan W. Bartlett
    Geert Molenberghs
    Pritibha Singh
    Ilya Lipkovich
    Michael O’Kelly
    Therapeutic Innovation & Regulatory Science, 2020, 54 : 370 - 384
  • [7] Defining Efficacy Estimands in Clinical Trials: Examples Illustrating ICH E9(R1) Guidelines
    Ratitch, Bohdana
    Goel, Niti
    Mallinckrodt, Craig
    Bell, James
    Bartlett, Jonathan W.
    Molenberghs, Geert
    Singh, Pritibha
    Lipkovich, Ilya
    O'Kelly, Michael
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2020, 54 (02) : 370 - 384
  • [8] Current Practices in Choosing Estimands and Sensitivity Analyses in Clinical Trials: Results of the ICH E9 Survey
    Fletcher, C.
    Tsuchiya, S.
    Mehrotra, D. V.
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2017, 51 (01) : 69 - 76
  • [9] Current Practices in Choosing Estimands and Sensitivity Analyses in Clinical Trials: Results of the ICH E9 Survey
    C. Fletcher
    S. Tsuchiya
    D. V. Mehrotra
    Therapeutic Innovation & Regulatory Science, 2017, 51 : 69 - 76
  • [10] Is Intention to Treat Still the Gold Standard or Should Health Technology Assessment Agencies Embrace a Broader Estimands Framework? Insights and Perspectives From the National Institute for Health and Care Excellence and Institut f?r Qualit?t und Wirtschaftlichkeit im Gesundheitswesen on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use E9 (R1) Addendum
    Morga, Antonia
    Latimer, Nicholas R.
    Scott, Martin
    Hawkins, Neil
    Schlichting, Michael
    Wang, Jixian
    VALUE IN HEALTH, 2023, 26 (02) : 234 - 242
1